HC Wainwright Upgrades FibroGen (NASDAQ:FGEN) to Strong-Buy

FibroGen (NASDAQ:FGEN) was upgraded by stock analysts at HC Wainwright to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. HC Wainwright also issued estimates for FibroGen’s FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

A number of other equities research analysts have also recently weighed in on FGEN. StockNews.com initiated coverage on FibroGen in a research note on Monday. They set a “hold” rating for the company. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Trading Down 1.6 %

NASDAQ:FGEN opened at $0.34 on Tuesday. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93. The stock has a fifty day simple moving average of $0.35 and a 200-day simple moving average of $0.57. The company has a market cap of $34.51 million, a price-to-earnings ratio of -0.28 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period last year, the firm earned ($0.52) earnings per share. As a group, equities research analysts predict that FibroGen will post -0.86 EPS for the current fiscal year.

Institutional Trading of FibroGen

A number of hedge funds have recently modified their holdings of FGEN. Geode Capital Management LLC grew its holdings in FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares during the period. FMR LLC grew its position in shares of FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in FibroGen in the 3rd quarter valued at $307,000. Point72 DIFC Ltd grew its holdings in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares during the period. Finally, Cubist Systematic Strategies LLC grew its stake in shares of FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares during the period. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.